肠道菌群-免疫轴:绝经后骨质疏松症发病机制与治疗干预的新视角

doi:10.3969/j.issn.1003-9198.2026.03.016

摘要/Abstract

摘要： 绝经后骨质疏松症(PMO)是一种常见于绝经后女性的骨骼疾病,严重影响其生活质量。研究表明,肠道菌群(GM)-免疫轴通过多种途径影响PMO的进程,对其深入研究有望为骨质疏松的防治带来新的突破。本文系统综述了GM-免疫轴在PMO中的作用,重点探讨其分子机制、治疗潜力、相关争议及未来展望。通过对相关文献的综合分析,提出未来的核心方向在于精准调控GM-免疫轴,例如设计特定的益生菌、益生元或药物,靶向调节GM的组成和功能,从而为骨质疏松等疾病的治疗提供新的策略。此外,结合GM调控与传统骨质疏松治疗药物,有望提高治疗效果,减少药物不良反应。

关键词: 绝经后骨质疏松症, 肠道菌群, 免疫细胞, 骨代谢

Abstract: Postmenopausal osteoporosis (PMO) is a common skeletal disorder among postmenopausal women, significantly impacting their quality of life. Research indicates that the gut microbiota (GM) -immune axis influences the progression of PMO through multiple pathways, and in-depth studies in this area are expected to bring new breakthroughs in the prevention and treatment of osteoporosis. This paper systematically reviews the role of the GM-immune axis in PMO, with a focus on its molecular mechanisms, therapeutic potential, associated controversies, and prospects. Through a comprehensive analysis of relevant literature, we propose that the core direction for future research lies in the precise regulation of the GM-immune axis, such as designing specific probiotics, prebiotics, or drugs to target and modulate the composition and function of GM, thereby providing novel strategies for the treatment of osteoporosis and related diseases. Furthermore, combining GM modulation with traditional anti-osteoporosis medications is expected to enhance therapeutic efficacy and reduce adverse drug reactions.

Key words: postmenopausal osteoporosis, gut microbiota, immune cells, bone metabolism

中图分类号:

R 681

刘月, 薛晴, 刘则坤, 刘冰, 齐昊. 肠道菌群-免疫轴:绝经后骨质疏松症发病机制与治疗干预的新视角[J]. 实用老年医学, 2026, 40(3): 304-308.

LIU Yue, XUE Qing, LIU Zekun, LIU Bing, QI Hao. Gut microbiota-immune axis: a new perspective on the pathogenesis and therapeutic interventions for postmenopausal osteoporosis[J]. Practical Geriatrics, 2026, 40(3): 304-308.

参考文献

[1] CHEN P, LI Z, HU Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review[J]. BMC Public Health, 2016, 16(1): 1039.
[2] YAO Y, CAI X, CHEN Y, et al. Estrogen deficiency-mediated osteoimmunity in postmenopausal osteoporosis[J]. Med Res Rev, 2025, 45(2): 561-575.
[3] SHIMOKAWA C. The gut microbiome-helminth-immune axis in autoimmune diseases[J]. Parasitol Int, 2025, 104: 102985.
[4] SAPRA L, SAINI C, MISHRA P K, et al. Bacillus coagulans ameliorates inflammatory bone loss in post-menopausal osteoporosis via modulating the “Gut-Immune-Bone” axis[J]. Gut Microbes, 2025, 17(1): 2492378.
[5] YU M, PAL S, PATERSON C W, et al. Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells[J]. J Clin Invest, 2021, 131(4): e143137.
[6] WANG N, MA S, FU L. Gut microbiota dysbiosis as one cause of osteoporosis by impairing intestinal barrier function[J]. Calcif Tissue Int, 2022, 110(2): 225-235.
[7] HSU S H, CHEN L R, CHEN K H. Primary osteoporosis induced by androgen and estrogen deficiency: the molecular and cellular perspective on pathophysiological mechanisms and treatments[J]. Int J Mol Sci, 2024, 25(22): 12139.
[8] DING P, TAN Q, WEI Z, et al. Toll-like receptor 9 deficiency induces osteoclastic bone loss via gut microbiota-associated systemic chronic inflammation[J]. Bone Res, 2022, 10(1): 42.
[9] LIU Y J, TANG B, WANG F C, et al. Parthenolide ameliorates colon inflammation through regulating Treg/Th17 balance in a gut microbiota-dependent manner[J]. Theranostics, 2020, 10(12): 5225-5241.
[10] IVANOV I I, TUGANBAEV T, SKELLY A N, et al. T cell responses to the microbiota[J]. Annu Rev Immunol, 2022, 40: 559-587.
[11] HATHAWAY-SCHRADER J D, POULIDES N A, CARSON M D, et al. Specific commensal bacterium critically regulates gut microbiota osteoimmunomodulatory actions during normal postpubertal skeletal growth and maturation[J]. JBMR Plus, 2020, 4(3): e10338.
[12] PARK J, KIM M, KANG S G, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway[J]. Mucosal Immunol, 2015, 8(1): 80-93.
[13] ASARAT M, APOSTOLOPOULOS V, VASILJEVIC T, et al. Short-chain fatty acids regulate cytokines and Th17/Treg cells in human peripheral blood mononuclear cells in vitro[J]. Immunol Invest, 2016, 45(3): 205-222.
[14] DUPRAZ L, MAGNIEZ A, ROLHION N, et al. Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal γδ T cells[J]. Cell Rep, 2021, 36(1): 109332.
[15] XU X, JIA X, MO L, et al. Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis[J]. Bone Res, 2017, 5: 17046.
[16] BHARDWAJ A, SAPRA L, MADAN D, et al. Gut-resident regulatory T cells (GTregs) play a pivotal role in maintaining bone health under postmenopausal osteoporotic conditions[J]. J Leukoc Biol, 2025, 117(4): qiaf008.
[17] HE W, XIE Z, THØGERSEN R, et al. Effects of calcium source, inulin, and lactose on gut-bone associations in an ovarierectomized rat model[J]. Mol Nutr Food Res, 2022, 66(8): e2100883.
[18] CHEN B, WEI J, ZHU R, et al. Fructus Ligustri Lucidi aqueous extract promotes calcium balance and short-chain fatty acids production in ovariectomized rats[J]. J Ethnopharmacol, 2021, 279: 114348.
[19] SAPIR-KOREN R, LIVSHITS G. Postmenopausal osteoporosis in rheumatoid arthritis: the estrogen deficiency-immune mechanisms link[J]. Bone, 2017, 103: 102-115.
[20] D’AMELIO P, GRIMALDI A, DI BELLA S, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis[J]. Bone, 2008, 43(1): 92-100.
[21] SAPRA L, BHARDWAJ A, MISHRA P K, et al. Regulatory B cells (Bregs) inhibit osteoclastogenesis and play a potential role in ameliorating ovariectomy-induced bone loss[J]. Front Immunol, 2021, 12: 691081.
[22] KHAN N, SUMMERS C W, HELBERT M R, et al. Effects of age, gender, and immunosuppressive agents on in vivo toll-like receptor pathway responses[J]. Hum Immunol, 2010, 71(4): 372-376.
[23] WANG H, TIAN G, PEI Z, et al. Bifidobacterium longum increases serum vitamin D metabolite levels and modulates intestinal flora to alleviate osteoporosis in mice[J]. mSphere, 2025, 10(3): e0103924.
[24] YU J, HANG Y, SUN W, et al. Anti-osteoporotic effect of Lactobacillus brevis AR281 in an ovariectomized mouse model mediated by inhibition of osteoclast differentiation[J]. Biology: Basel, 2022, 11(3): 359.
[25] WANG Z, CHEN K, WU C, et al. An emerging role of Prevotella histicola on estrogen deficiency-induced bone loss through the gut microbiota-bone axis in postmenopausal women and in ovariectomized mice[J]. Am J Clin Nutr, 2021, 114(4): 1304-1313.
[26] CHEN W J, WANG X L, WANG Y F, et al. LPL-RH suppresses bone loss in ovariectomised rat models[J]. BMC Microbiol, 2024, 24(1): 545.
[27] TAO H, LI W, ZHANG W, et al. Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-κB activated pyroptosis pathways[J]. Pharmacol Res, 2021, 174: 105967.
[28] WANG Z, QI G, LI Z, et al. Effects of urolithin A on osteoclast differentiation induced by receptor activator of nuclear factor-κB ligand via bone morphogenic protein 2[J]. Bioengineered, 2022, 13(3): 5064-5078.
[29] PLOTTEL C S, BLASER M J. Microbiome and malignancy[J]. Cell Host Microbe, 2011, 10(4): 324-335.
[30] DE SIRE A, DE SIRE R, CURCI C, et al. Role of dietary supplements and probiotics in modulating microbiota and bone health: the gut-bone axis[J]. Cells, 2022, 11(4): 743.
[31] LI A, KOU R, WANG J, et al. 2′-Fucosyllactose ameliorates aging-related osteoporosis by restoring gut microbial and innate immune homeostasis[J]. J Adv Res, 2025, 75: 651-662.
[32] AI T, SHANG L, LI B, et al. Konjac oligosaccharides alleviated ovariectomy-induced bone loss through gut microbiota modulation and Treg/Th17 regulation[J]. J Agric Food Chem, 2024, 72(14): 7969-7979.
[33] LI X, LIU L, CAO Z, et al. Gut microbiota as an “invisible organ” that modulates the function of drugs[J]. Biomed Pharmacother, 2020, 121: 109653.
[34] ZHANG Y, CHEN Y, XIA J, et al. Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota[J]. Appl Microbiol Biotechnol, 2024, 108(1): 469.
[35] ZHANG Y L, CHEN Q, ZHENG L, et al. Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss[J]. World J Gastroenterol, 2022, 28(13): 1315-1328.
[36] LI X, XUE C, YANG Y, et al. Therapeutic effects of Isaria felina on postmenopausal osteoporosis: modulation of gut microbiota, metabolites, and immune responses[J]. Front Immunol, 2025, 16: 1508634.
[37] CHEN X C, LI W J, ZENG J Y, et al. Shengu granules ameliorate ovariectomy-induced osteoporosis by the gut-bone-immune axis[J]. Front Microbiol, 2024, 15: 1320500.
[38] DAMANI J J, DE SOUZA M J, VANEVERY H L, et al. The role of prunes in modulating inflammatory pathways to improve bone health in postmenopausal women[J]. Adv Nutr, 2022, 13(5): 1476-1492.
[39] CABINIAN A, SINSIMER D, TANG M, et al. Gut symbiotic microbes imprint intestinal immune cells with the innate receptor SLAMF4 which contributes to gut immune protection against enteric pathogens[J]. Gut, 2018, 67(5): 847-859.